TSXV - Delayed Quote CAD

BioSyent Inc. (RX.V)

8.51

+0.11

(+1.31%)

At close: April 25 at 2:16 PM EDT

BioSyent to Attend Planet MicroCap Showcase

MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th – May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent, will attend a Fireside Q&A session for investors at the conference on Wednesday, May 1st at 2:30pm PDT. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during th

GlobeNewswire 2 days ago

BIOYF
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032. “RepaGyn® and Proktis-M® have been part of our product portfolio since

GlobeNewswire 10 days ago

BIOYF
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Tuesday, April 16 and Wednesday, April 17, 2024. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent’s business and corporate activi

GlobeNewswire 15 days ago

BIOYF
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year

MISSISSAUGA, Ontario, April 03, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and physicians(1). This year marks the ninth consecutive year that FeraMAX® has been awarded this vote of confidence from physicians and pharmacists across Canada, including those professionals in Quebec. The annual Survey on OTC Counselling and Recommenda

GlobeNewswire 22 days ago

BIOYF
BioSyent to Present at LD Micro New York Investor Conference

MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the LD Micro Invitational XIV Conference in New York City on Tuesday, April 9th at 8:00am EDT. This presentation will also be live-streamed virtually. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on April 9th. These one-on-one me

GlobeNewswire 24 days ago

BIOYF
BioSyent Announces Grant of Restricted Share Units

MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date. About BioSyent Inc. Listed on the TSX

GlobeNewswire 29 days ago

BIOYF
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023

MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023. Key highlights include: (CAD)Q4 2023% Change vs. Q4 2022FY 2023% Change vs. FY 2022Canadian Pharma Sales7,989,09810%29,554,89913%International Pharma Sales54,750-54%1,047,74753%Total Company Sales8,273,68611%31,590,30213%EBITDA11,650,3015%7,926,4787%Net Income After Taxes (NIAT)1,450,79121

GlobeNewswire last month

BIOYF
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024

MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on Wednesday, March 13th after market hours. A presentation on the Company’s fourth quarter and full year 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exc

GlobeNewswire last month

BIOYF
Why You Might Be Interested In BioSyent Inc. (CVE:RX) For Its Upcoming Dividend

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see BioSyent Inc...

Simply Wall St. 2 months ago

BIOYF
BioSyent Named to 2024 TSX Venture 50

MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top performers on the TSX Venture Exchange. The TSX Venture 50 is an annual ranking of the top performing companies from the past year on the TSX Venture Exchange. The TSX Venture 50 recognizes the top 10 companies from each of five sectors: Clean Technology and Life Sciences, Diversified Ind

GlobeNewswire 2 months ago

BIOYF
BioSyent Declares First Quarter 2024 Dividend

MISSISSAUGA, Ontario, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. This first quarter 2024 dividend of $0.045 per common share represents a 12.5% increase from the fourth quarter 2023 dividend of $0.040 per common share

GlobeNewswire 2 months ago

BIOYF
BioSyent Announces Renewal of Normal Course Issuer Bid

MISSISSAUGA, Ontario , Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 650,000 of its common shares (“Shares”) over a 12-month period, representing approximately 5.53% of the Shares outstanding as of December 13, 2023. The NCIB will commence on D

GlobeNewswire 4 months ago

BIOYF
Is It Smart To Buy BioSyent Inc. (CVE:RX) Before It Goes Ex-Dividend?

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see BioSyent Inc...

Simply Wall St. 4 months ago

BIOYF
BioSyent Announces the Availability of Gelclair® in Canada

New Treatment for Painful Mouth Sores Due to Cancer TherapyMISSISSAUGA, Ontario, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of its new oncology supportive care product, Gelclair®, to wholesalers in Canada. Gelclair® is indicated for the relief of the painful symptoms of oral mucositis. Oral mucositis (mouth sores and / or ulcers) is an adverse effe

GlobeNewswire 5 months ago

BIOYF
BioSyent (CVE:RX) Has Affirmed Its Dividend Of CA$0.04

BioSyent Inc. ( CVE:RX ) will pay a dividend of CA$0.04 on the 15th of December. This means that the annual payment...

Simply Wall St. 5 months ago

BIOYF
BioSyent Releases Q3 and YTD 2023 Financial Results

MISSISSAUGA, Ontario, Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2023. Key highlights include: (CAD)Q3 2023% Change vs. Q3 2022YTD 2023% Change vs. YTD 2022Trailing Twelve Months (TTM) Sept 30, 2023% Change vs. TTM Sept 30, 2022Canadian Pharma Sales7,432,36117%21,565,80114%28,854,82413%International Pharma Sales992,997100%992,99776%1,110,78826%Total Company

GlobeNewswire 5 months ago

BIOYF
BioSyent Declares Fourth Quarter 2023 Dividend

MISSISSAUGA, Ontario, Nov. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. This fourth quarter 2023 dividend compares with the third quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an 'eligible div

GlobeNewswire 5 months ago

BIOYF
BioSyent Schedules Q3 and YTD 2023 Earnings Release for November 16, 2023

MISSISSAUGA, Ontario, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2023 on Thursday, November 16, 2023 before market hours. A presentation on the Company’s third quarter and year-to-date 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture

GlobeNewswire 5 months ago

BIOYF
BioSyent Launches "menopauseinformation.ca" on World Menopause Day

MISSISSAUGA, Ontario, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce the launch of menopauseinformation.ca, a comprehensive online platform designed to empower peri-menopausal and menopausal women across Canada. Menopause is a natural transition that every woman experiences, and understanding this transition is crucial for a smoother journey. The menopauseinformation.ca website aims to provide vital information and resources to help women nav

GlobeNewswire 6 months ago

BIOYF
TSX Venture Exchange Stock Maintenance Bulletins

TSX VENTURE COMPANIES

CNW Group 7 months ago

REE.V

BIOYF

JPOTF

Performance Overview

Return	RX.V	S&P/TSX Composite index
YTD	-7.21%	+4.42%
1-Year	+12.08%	+5.85%
3-Year	+11.87%	+14.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioSyent Inc. (RX.V)

BioSyent to Attend Planet MicroCap Showcase

BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year

BioSyent to Present at LD Micro New York Investor Conference

BioSyent Announces Grant of Restricted Share Units

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023

BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024

Why You Might Be Interested In BioSyent Inc. (CVE:RX) For Its Upcoming Dividend

BioSyent Named to 2024 TSX Venture 50

BioSyent Declares First Quarter 2024 Dividend

BioSyent Announces Renewal of Normal Course Issuer Bid

Is It Smart To Buy BioSyent Inc. (CVE:RX) Before It Goes Ex-Dividend?

BioSyent Announces the Availability of Gelclair® in Canada

BioSyent (CVE:RX) Has Affirmed Its Dividend Of CA$0.04

BioSyent Releases Q3 and YTD 2023 Financial Results

BioSyent Declares Fourth Quarter 2023 Dividend

BioSyent Schedules Q3 and YTD 2023 Earnings Release for November 16, 2023

BioSyent Launches "menopauseinformation.ca" on World Menopause Day

TSX Venture Exchange Stock Maintenance Bulletins

Performance Overview